Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. - Test2 - elhamkhani - TriplyDB

Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition.

Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition.

http://www.wikidata.org/entity/Q36725676

about

SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people Genetic variants associated with neurodegenerative Alzheimer disease in natural models Three dimensions of the amyloid hypothesis: time, space and 'wingmen'Molecular profiling reveals diversity of stress signal transduction cascades in highly penetrant Alzheimer's disease human skin fibroblasts GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement.Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels.The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers An epigenetic signature in peripheral blood associated with the haplotype on 17q21.31, a risk factor for neurodegenerative tauopathy.Biomarkers in translational research of Alzheimer's disease Cerebrospinal fluid biomarkers of Alzheimer's disease.Transgenic Drosophila models of Alzheimer's disease and tauopathies Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease Targeting Abeta and tau in Alzheimer's disease, an early interim report Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease.Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation Alzheimer's disease risk genes and mechanisms of disease pathogenesis Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels.Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease.Regulation of human MAPT gene expression.Fluid biomarkers in Alzheimer disease.Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies.Finding risk in all the right places Antisense reduction of tau in adult mice protects against seizures An inflection point in gene discovery efforts for neurodegenerative diseases: from syndromic diagnoses toward endophenotypes and the epigenome.Genetic control of human brain transcript expression in Alzheimer disease.Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: the Cache County Dementia Progression Study.Genome sequencing in a case of Niemann-Pick type C Calcium phosphatase calcineurin influences tau metabolism.Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.Genetic discoveries in AD using CSF amyloid and tau.Alzheimer's disease: the challenge of the second century.CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.Alternative Approaches in Gene Discovery and Characterization in Alzheimer's Disease.

P2860

Q21144971-6DED5F88-EAD5-48A3-B146-044C4A5CA60E Q22253051-758EDD78-98A2-49A4-B732-48FB5D5470AD Q28079843-4EC00FAB-0DFB-45DC-9846-41C7C417CE21 Q28082768-12B2FE98-87ED-4ED4-BB0D-33E6646D12A3 Q28474877-DD92046C-3076-43CF-BB65-BB0A190FAA71 Q29417137-9046D06D-6682-4CC8-A568-35A1A3556CE3 Q30572288-E370AC5F-AC3E-4EC0-BF6E-AF50855608D5 Q30592862-9BACB9A7-844B-4FC1-964E-369C1F6D35CC Q31129910-3E2433BB-5E3D-4FD6-ADDF-36FE90D26058 Q31153643-E0AE4C84-F4FC-4122-B5C0-0DD3272A6232 Q33556189-9A777050-CF1B-4424-B011-62F9130164BB Q33757828-7525D731-E493-4379-8AC2-185D2E90B365 Q33770749-10A2BA3C-25BB-42A1-A6DB-46EE685FD46D Q33828778-78D3FD9C-4D92-442F-BB92-3AED504A4129 Q33829008-B8164176-1808-4B7F-87AB-AF2651C79713 Q33980306-B4B560E8-AEB6-4F17-9B47-3814225BDA37 Q34394932-ECD91018-06AA-4A62-903B-094338482337 Q34425904-D70A7536-A743-4C16-A7E4-687C511E64CD Q34544940-B3B9C1F4-81CB-4504-9954-781B87239578 Q34661700-91193E6D-3115-46F6-8735-42540498E0CF Q34959322-17EB2707-879D-405D-AC44-C74D734AE817 Q35484526-3023AFCE-5395-4760-B210-DA40ED6F2C52 Q35844758-F89A7D20-7CA5-4616-9543-AE02E4AD45FB Q36186513-792E48FB-6C17-4673-8706-61FCC387F0E5 Q36283394-2AFA22A6-4B97-4933-910F-E8D730059242 Q36466732-B1FF5E93-22C8-4556-A7DB-36137AEAF559 Q36860474-3A046A88-DB5A-4063-844D-4F3828A3F15E Q37058143-6410737F-C3C8-45AE-8FE5-BB7F0133449B Q37066475-9B999CF2-3873-4DFE-9D56-882C89BA9BF1 Q37156046-85D4F2BA-DC6D-4CA4-8B43-4D16E43B0D90 Q37227424-835CFF95-898C-4A76-9FF4-6F71E0CE5DAA Q37228718-EDC8234F-4EF8-4CCA-87FA-96E34D512806 Q37258203-322F4A61-FF28-4472-8F13-107579C462A6 Q37416674-122CCC72-9486-428D-9A78-CBBEC62527CB Q37427768-DAA3D9ED-1E67-4DA8-8B5D-942847CBD5D7 Q37438267-D9EAB47B-CD5F-43B8-9FC7-45126F86A02B Q37692079-3BD7BBFA-D943-4369-AF69-2EC87D39162C Q37862502-5B784480-AAEE-4105-9411-CEE94CFEA775 Q37953330-43E942CB-150B-4BDD-9ECA-850B939F4680 Q38088622-4DBF7FC9-6F02-49BE-BB12-A61537892361

P2860

Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition.

http://www.wikidata.org/entity/Q36725676

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Variation in MAPT is associate ...... ce of amyloid-beta deposition.

@ast

Variation in MAPT is associate ...... ce of amyloid-beta deposition.

@en

type

label

Variation in MAPT is associate ...... ce of amyloid-beta deposition.

@ast

Variation in MAPT is associate ...... ce of amyloid-beta deposition.

@en

prefLabel

Variation in MAPT is associate ...... ce of amyloid-beta deposition.

@ast

Variation in MAPT is associate ...... ce of amyloid-beta deposition.

@en

P1433

Q36725676-E9BC9B79-050C-47FD-8810-E704AA6528B5

P1476

Q36725676-48A85604-C4EB-42B1-AFB5-D6352F6BB9D0

P2093

Q36725676-2B759C2C-920B-40AD-BEA5-4D8915168A1A

Q36725676-36698466-173D-4087-A5D6-917E2640B389

Q36725676-B830D041-156D-4B79-826D-783B1E00F8EA

Q36725676-E0DD7792-DB3D-4B05-8E57-94FDB69069B2

P2860

Q36725676-0E1A8989-2CD1-4A20-8F83-45365CCB97A9

Q36725676-0EC74222-F03F-45BA-B9FB-3365BC97C778

Q36725676-21F19235-AD3C-4ECB-B311-9A8137C96254

Q36725676-2262ABC6-3309-447E-8BE4-AE78F4D4CAD7

Q36725676-360C7D8E-1AB4-41F8-9276-23419AE3DA0E

Q36725676-424E6E6B-5C35-4C5F-8DA7-1B194CF8903B

Q36725676-50026235-FDF0-4BA7-A1B9-1CD5266F12EB

Q36725676-50361F27-3DD1-4A93-B0FB-7DBB92668C9F

Q36725676-55EE1B6E-E1D4-4DDB-95F2-69972E9DCFA9

Q36725676-571B718F-B5C2-4442-BFB7-669898B5542F

P304

Q36725676-B3202AC3-62A1-4EE3-82E0-AB2E94C89689

P31

Q36725676-11173F2B-EBD8-47DA-811E-3D9B78AC7FF3

P356

Q36725676-C9BC13AA-C100-4AB2-B7C7-251564D0826F

P407

Q36725676-036FCE3D-5FC0-462E-A653-AF173573DA7A

P433

Q36725676-896EC8D3-1B70-4353-A6B7-7F5DEB1E08FB

P478

Q36725676-B036AC2F-BF42-4788-834E-D2E17A72FAF4

P50

Q36725676-196C3184-D506-4722-84E8-D5DD7AE8204D

Q36725676-2D252175-F484-420B-A492-F7DE9CC7229D

Q36725676-54F9F75E-3B6E-41A1-BEFE-DFF52E43944C

Q36725676-73C78B9F-1906-41F0-967D-EC8F32FE155B

Q36725676-7EDB4079-1870-45B7-BBC3-4831AA19E318

Q36725676-81DCFE73-2D27-4741-967C-07B68288139F

Q36725676-835F282A-A2DC-45A8-9662-1AEAE0529A3A

Q36725676-ED24B831-3804-4778-8326-D625AAEE343E

P577

Q36725676-85575186-5129-4D97-8B8E-E7FEB10DF328

P5875

Q36725676-9FF21A02-9EA8-425C-8FBF-D92254A2D36D

P698

Q36725676-0DFB46BA-3680-413C-A728-6F872CCC98EF

P921

Q36725676-6BA10D3A-E84B-4CC3-B742-7445C6F4E03B

P932

Q36725676-FEB6E680-21C8-4AB1-8372-AE893B45F7EA

P356

PNAS.0801227105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Variation in MAPT is associate ...... ce of amyloid-beta deposition.

@en

P2093

John S K Kauwe

http://www.w3.org/2001/XMLSchema#string

Kevin Mayo

http://www.w3.org/2001/XMLSchema#string

Petra Nowotny

http://www.w3.org/2001/XMLSchema#string

Sarah Bertelsen

http://www.w3.org/2001/XMLSchema#string

P2860

Statistical significance for genomewide studies

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Haploview: analysis and visualization of LD and haplotype maps

The Clinical Dementia Rating (CDR): current version and scoring rules

Processing of gene expression data generated by quantitative real-time RT-PCR.

Biomarkers in the diagnosis of Alzheimer's disease: are we ready?

CT60 genotype does not affect CTLA-4 isoform expression despite association to T1D and AITD in northern Sweden.

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.

Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration.

CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.

P304

8050-8054

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0801227105

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Daniela Galimberti

Carlos Cruchaga

David M. Holtzman

Chiara Fenoglio

P577

2008-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5315337

http://www.w3.org/2001/XMLSchema#string

P698

18541914

http://www.w3.org/2001/XMLSchema#string

P921

cerebrospinal fluid

P932

2430357

http://www.w3.org/2001/XMLSchema#string